SCHEMBL6717170

SCHEMBL6717170

COC(=O)c1ccc(NC(=S)NC(CC(C)C)C(=O)Nc2c(C)cccc2C)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STAT3 P40763 1/20 0.55
MMP1 P03956 1/20 0.53
MMP3 P08254 1/20 0.53
MMP7 P09237 1/20 0.53
ANPEP P15144 1/20 0.52
GAA P10253 3/20 0.50
HPGD P15428 1/20 0.50
MAPT P10636 5/20 0.49
MEN1 O00255 4/20 0.49
KMT2A Q03164 4/20 0.49
ALOX12 P18054 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
POLB P06746 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
ALDH1A1 P00352 4/20 0.46
LMNA P02545 2/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
CA1 P00915 2/20 0.45
CA2 P00918 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6715869 0.88 MAPT (0.59) STAT3MMP1MMP3MMP7ANPEP
SCHEMBL6717225 0.75 MAPT (0.58) STAT3GAAMAPTMEN1KMT2A
SCHEMBL13764939 0.74 FPR2 (0.56) STAT3ANPEPHPGDMAPTALOX12
SCHEMBL6714247 0.74 MAPT (0.62) STAT3GAAHPGDMAPTMEN1
SCHEMBL8346734 0.74 MAPT (0.62) STAT3GAAHPGDMAPTMEN1
SCHEMBL6716813 0.74 MAPT (0.62) STAT3GAAHPGDMAPTMEN1
SCHEMBL6717319 0.74 ALDH1A1 (0.54) ANPEPGAAHPGDMAPTALOX12
SCHEMBL8345950 0.73 ANPEP (0.46) ANPEPMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL6714162 0.72 MEN1 (0.56) MAPTMEN1KMT2ASMN1; SMN2POLB
SCHEMBL7763096 0.71 MMP3 (0.80) STAT3MMP1MMP3MMP7ANPEP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 US disclosed
WO-2004022534-A1 ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors SLC1A2, SLC6A7, SLC1A1 STAT3 4711/4885MMP1 1538/4885MMP3 1070/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.